Stryker Corp
SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3024% below fair value
$306.81+14.95 (+5.12%)
Close on Nov 2, 2026Market cap $117.68BP/E 32.7Yield –
Stryker MedSurg & Neurotechnology by Quarter
MedSurg & Neurotechnology — Selling Price Growth Impact YoY (%) (%)
Stryker MedSurg & Neurotechnology: 0.2% in Q3 2026, down 0.6 pts from a year earlier.
Latest, Q3 2026
0.2%
Period ended Sep 30, 2026
Change on a year earlier
-0.6 pts
0.8% in Q3 2025
History
14 quarters
Since Q2 2022
Sources
14
Documents cited below
Where the Q3 2026 figure comes from
“Excluding the 0.1% impact of acquisitions and divestitures, net sales in constant currency increased by 8.9% from increased unit volume and 0.2% from higher prices.”
Reported in Stryker Form 10-Q & Form 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Stryker MedSurg & Neurotechnology (%), quarterly Q2 2022–Q3 2026 [Data set]. Compiled from Stryker SEC filings and investor materials. https://stockdatahq.com/stocks/syk/kpis/core-medsurg-price
See every metric in the Stryker KPI table. Data updated Nov 2, 2026.